dNP2-ctCTLA-4 inhibits German cockroach extract-induced allergic airway inflammation and hyper-responsiveness via inhibition of Th2 responses.
- Author:
Sangho LIM
1
;
Jung Ho SOHN
;
Ja Hyun KOO
;
Jung Won PARK
;
Je Min CHOI
Author Information
- Publication Type:Original Article
- MeSH: Abatacept; Administration, Intranasal; Allergens; Antibodies; Asthma; Biological Products; Blattellidae*; Bronchi; Collagen; Cytoplasm; Eosinophils; Epithelium; Family Characteristics; Goblet Cells; Inflammation*; Interleukin-13; Interleukin-4; Interleukin-5; Lung; Metaplasia; Respiratory Hypersensitivity; T-Lymphocytes; T-Lymphocytes, Cytotoxic
- From:Experimental & Molecular Medicine 2017;49(8):e362-
- CountryRepublic of Korea
- Language:English
- Abstract: German cockroaches are major household allergens that can trigger allergic airway inflammatory diseases with sensitive T-cell responses. Although the use of immune modulatory biologics, such as antibodies, to mediate allergic responses has recently been examined, only systemic administration is available because of the size limitations on intranasal administration. Here we utilized a cell-permeable peptide, dNP2, to deliver the cytoplasmic domain of cytotoxic T-lymphocyte antigen-4 (ctCTLA-4) through the airway epithelium to modulate Th2 responses in a German cockroach extract (GCE)-induced allergic airway inflammation model. The intranasal delivery efficiency of the dNP2-dTomato protein to the lungs was higher in GCE-induced asthmatic lung parenchymal cells compared to the sham cells. Intranasal administration of the dNP2-ctCTLA-4 protein inhibited airway hyper-responsiveness and reduced airway inflammation and remodeling, including goblet cell metaplasia and collagen deposition around the bronchi. The number of infiltrated cells, including eosinophils, and the levels of IL-4, IL-5, IL-13 and IFN-γ in the lungs were significantly reduced, presumably owing to inhibition of Th2 differentiation. However, intranasal administration of CTLA4-Ig did not inhibit airway inflammation. These results collectively suggest that dNP2-ctCTLA-4 is an efficient intranasally applicable candidate biologic for treating allergic asthma.
